October 2014: Recent Papers Using Luminex xMAP Technology

10月 21st, 2014 / Luminex Corporation

Luminex® xMAP® Technology has become an indispensable tool for tens of thousands of life science researchers. Here are six new papers, featuring customer-developed assays and partner kits, which we thought would be especially interesting to you.

Our bibliography helps you stay current with the success that your scientific peers are having while using xMAP Technology. We’ve included hyperlinks to the PubMed citation or journal site for your convenience.

A complete list of over 22,000 publications using Luminex can be found at www.luminexcorp.net/publications.

Affinity Proteomics Screening

Bachmann J, Burte F, Pramana S, Conte I, Brown BJ, Orimadegun AE, Ajetunmobi WA, Afolabi NK, Akinkunmi F, Omokhodion S, Akinbami FO, Shokunbi WA, Kampf C, Pawitan Y, Uhlen M, Sodeinde O, Schwenk JM, Wahlgren M, Fernandez-Reyes D, Nilsson P. Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. PLoS Pathogens 2014;10(4):U137-U148.

October xMAP Research

FIGURE 1: Overview of affinity proteomics screening and study design.

A. Schematic overview of the affinity proteomics approach using antibody suspension bead arrays. Plasma samples were biotinylated, antibodies were coupled to color-coded magnetic beads, and both were combined for analysis. Bead identity and captured plasma proteins were then detected using a flow cytometric analyzer. B. Experimental design of study. Initial screening with 1,132 antibodies from targeted and blinded selections was performed in the discovery cohort (n=356). Data from the patient groups were compared using univariate tests and multivariate penalized regression models. Identified single proteins and multi-component protein panels discriminating the 3 disease groups were validated in the verification cohort (n=363).

Cytokine Profiling

Lynch HE, Sanchez AM, D’Souza MP, Rountree W, Denny TN, Kalos M, Sempowski GD. Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. Journal of Immunological Methods 2014;409(62–71).

Suh JM, Jonker JW, Ahmadian M, Goetz R, Lackey D, Osborn O, Huang Z, Liu W, Yoshihara E, van Dijk TH, Havinga R, Fan W, Yin Y-Q, Yu RT, Liddle C, Atkins AR, Olefsky JM, Mohammadi M, Downes M, Evans RM. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014;513(7518):436–439.

von Burg N, Chappaz S, Baerenwaldt A, Horvath E, Dasgupta SB, Ashok D, Pieters J, Tacchini-Cottier F, Rolink A, Acha-Orbea H, Finke D. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. Proceedings of the National Academy of Sciences of the United States of America 2014;111(35):12835–12840.

Gene Expression

Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev AE, Schuele B, Alexander J, Wallace W, Halliday GM, Langston JW, Braxton S, Yednock T, Shaler T, Johnston JA. Systems-based analyses of brain regions functionally impacted in Parkinson’s disease reveals underlying causal mechanisms. PLoS One 2014;9(8):U61-U74.

HLA Testing

Schaub S, Hoenger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014;98(4):387–393.